By Karen Roman
ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025.
The findings confirm elevated inflammatory biomarkers in newborns with HIE and demonstrate a predictable way the body interacts with RLS-0071 (pegtarazimod), the company stated.
“These biomarker findings represent a significant advancement in our understanding of the inflammatory pathways driving HIE in humans,” said Kenji M. Cunnion, MD, MPH, ReAlta’s Chief Medical Officer.
Contact:
